<code id='521EAAEB03'></code><style id='521EAAEB03'></style>
    • <acronym id='521EAAEB03'></acronym>
      <center id='521EAAEB03'><center id='521EAAEB03'><tfoot id='521EAAEB03'></tfoot></center><abbr id='521EAAEB03'><dir id='521EAAEB03'><tfoot id='521EAAEB03'></tfoot><noframes id='521EAAEB03'>

    • <optgroup id='521EAAEB03'><strike id='521EAAEB03'><sup id='521EAAEB03'></sup></strike><code id='521EAAEB03'></code></optgroup>
        1. <b id='521EAAEB03'><label id='521EAAEB03'><select id='521EAAEB03'><dt id='521EAAEB03'><span id='521EAAEB03'></span></dt></select></label></b><u id='521EAAEB03'></u>
          <i id='521EAAEB03'><strike id='521EAAEB03'><tt id='521EAAEB03'><pre id='521EAAEB03'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:934

          Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

          advertisement

          For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          Adam's Take: Intra
          Adam's Take: Intra

          MollyFerguson/STATIamoneweekawayfromthelaunchofmyweeklyemailnewsletter!It’scalledAdam’sBiotechScorec

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          As the dark side of IVF slowly comes into focus, even more transparency is needed

          AselectionofIVFhormonebottlesandsyringesattheScienceMuseuminLondon,England.LeonNeal/GettyImagesIwas1